

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Robert Jiang et al.

Confirmation No.: Not Assigned

Serial No.: 10/759,555

Group Art Unit: Not Assigned

Filing Date: January 16, 2004

Examiner: Not Assigned

Title: SUBSTITUTED HETEROCYCLIC COMPOUNDS

INFORMATION DISCLOSURE STATEMENT


Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

U.S. PATENT DOCUMENTS		
Document No.	Issue Date or Publication Date	Name of Patentee or Applicant
U.S. Patent No. 4,588,129	12-10-1985	Kluge et al.
U.S. Patent No. 4,567,264	1-28-1986	Kluge et al.
U.S. Patent No. 4,766,125	8-23-1988	Van Daele et al.
U.S. Patent No. 5,472,707	12-5-1995	Samuels et al.
U.S. Patent No. 5,506,229	4-9-96	Dow et al.
U.S. Patent No. 5,906,988	5-0-1999	Dow
U.S. Patent No. 6,451,798	9-17-2002	Varkhedkar et al.
U.S. Patent No. 6,552,023	04-22-2003	Zablocki et al.
U.S. Patent No. 6,573,264	6-3-2003	Zablocki et al.
U.S. Patent No. 6,677,336	2-7-2002	Zablocki et al.
U.S. Patent No. 6,638,970	10-28-2003	Elzein et al.
U.S. Patent No. 6,677,343	1-13-04	Blackburn et al.
US 2003/0181352	9-25-2003	Ibrahim et al.
U. S. Patent Application Serial No. 10/729,499	Filing Date 12-5-03	Elzein et al.



U.S. PATENT DOCUMENTS

Document No.	Issue Date or Publication Date	Name of Patentee or Applicant
U. S. Patent Application Serial No. 10/745,224	Filing Date 12-19-03	Ibrahim et al.

FOREIGN PATENT DOCUMENTS

Document No.	Publication Date	Country
0 407 780	Jan., 1991	EP.
0 483 392	June, 1992	EP.
WO 01/62749	Aug., 2001	WO.
03 141258 A	June, 1991	JP

NONPATENT DOCUMENTS

McCormick, et al. "Ranolazine: A Novel Metabolic Modulator for the Treatment of Angina", Gen Pharmac., vol. 30, No. 5, pp. 639-645, (1998).

Suzuki T et al: "Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer.", Journal of Chemistry, vol. 40, no. 13, 1997, pages 2047-2052, XP000924067, the whole document, particularly page 2049, table 2, compound 5

Zacharowski K et al: "Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat." European Journal of Pharmacology, vol. 418, no. 1-2, April 20, 2001, pages 105-110, XP002215620, the whole document

Lopaschuk G D: "Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism", The American Journal of Cardiology, vol. 82, no. 5A, September 3, 1997, pages 14K-17K, XP002215621, the whole document


As the subject application was filed after June 30, 2003, copies of the U.S. patents and/or publications disclosed in this Information Disclosure Statement are not required and, therefore, are not included.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

Respectfully submitted,

By:


J. Elin Hartrum
Registration No. 43,663

CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, California 94304
Telephone: (650) 384-8755
Facsimile: (650) 475-0359

JUN 03 2004

C-10
O I P E

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	03-0185
-------	---	----	---	------------------------	---------

Complete if Known

Application Number	10/759,555
Filing Date	January 16, 2004
First Named Inventor	Robert Jiang
Art Unit	
Examiner Name	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
		U.S. Patent No. 4,588,129	12-10-1985	Kluge et al.			
		U.S. Patent No. 4,567,264	1-28-1986	Kluge et al.			
		U.S. Patent No. 4,766,125	8-23-1988	Van Daele et al.			
		U.S. Patent No. 5,472,707	12-5-1995	Samuels et al.			
		U.S. Patent No. 5,506,229	4-9-96	Dow et al.			
		U.S. Patent No. 5,906,988	5-0-1999	Dow			
		U.S. Patent No. 6,451,798	9-17-2002	Varkhedkar et al.			
		U.S. Patent No. 6,552,023	04-22-2003	Zablocki et al.			
		U.S. Patent No. 6,573,264	6-3-2003	Zablocki et al.			
		U.S. Patent No. 6,677,336	2-7-2002	Zablocki et al.			
		U.S. Patent No. 6,638,970	10-28-2003	Elzein et al.			
		U.S. Patent No. 6,677,343	1-13-04	Blackburn et al.			
		US 2003/0181352	9-25-2003	Ibrahim et al.			
		U. S. Patent Application Serial No. 10/729,499		Elzein et al.			12-5-03
		U. S. Patent Application Serial No. 10/729,499		Jiang et al.			1-16-04

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
		0 407 780	Jan., 1991	EP.			
		0 483 392	June, 1992	EP.			
		WO 01/62749	Aug., 2001	WO.			
		03 141258 A	June, 1991	JP			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		MCCORMICK, et al. "Ranolazine: A Novel Metabolic Modulator for the Treatment of Angina", Gen Pharmac., vol. 30, No. 5, pp. 639-645, (1998).	
		SUZUKI T et al: "Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer.", Journal of Chemistry, vol. 40, no. 13, 1997, pages 2047-2052, XP000924067, the whole document, particularly page 2049, table 2, compound 5	
		ZACHAROWSKI K et al: "Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat." European Journal of Pharmacology, vol. 418, no. 1-2, April 20, 2001, pages 105-110, XP002215620, the whole document	
		LOPASCHUK G D: "Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism", The American Journal of Cardiology, vol. 82, no. 5A, September 3, 1997, pages 14K-17K, XP002215621, the whole document	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.